Monopar Therapeutics MNPR Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's additional paid-in capital?
- Monopar Therapeutics (MNPR) reported additional paid-in capital of $228.69M in Q1 2026.
- How has Monopar Therapeutics's additional paid-in capital changed year-over-year?
- Monopar Therapeutics's additional paid-in capital increased by 73.2% year-over-year, from $132.03M to $228.69M.
- What is the long-term trend for Monopar Therapeutics's additional paid-in capital?
- Over 3 years (2022 to 2025), Monopar Therapeutics's additional paid-in capital has grown at a 54.3% compound annual growth rate (CAGR), from $61.87M to $227.2M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.